Linaglite-DM 5/10/500 Tablet

Linagliptin 5 mg + Dapagliflozin 10 mg + Metformin 500 mg (SR)

Linaglite-DM 5/10/500 Tablet — Linagliptin 5 mg + Dapagliflozin 10 mg + Metformin 500 mg (Sustained Release) from Trumac Healthcare PCD Pharma Franchise India

Composition Linagliptin 5 mg + Dapagliflozin 10 mg + Metformin 500 mg (Sustained Release)
Dosage Form Tablet
Pack Type Box
Pack Size 10 x 10 (Alu Alu)
MRP ₹ 2190
Therapy Cardiac + Diabetic — DPP-4 inhibitor + SGLT2 inhibitor + biguanide (Triple OAD)
Storage Store below 25°C.

📱 WhatsApp Enquiry📞 Call: +919041677932

About Linaglite-DM 5/10/500 Tablet

Linaglite-DM Tablet is a triple oral antidiabetic combining Linagliptin 5 mg (DPP-4 inhibitor), Dapagliflozin 10 mg (SGLT2 inhibitor) and Metformin 500 mg (biguanide, sustained release). The three mechanisms together address insulin secretion, urinary glucose excretion and hepatic glucose output.

It is indicated for type-2 diabetes inadequately controlled on dual oral therapy, or where simultaneous initiation of three mechanisms is preferred for significantly elevated HbA1c.

Camrut Healthcare manufactures Linaglite-DM under WHO-GMP conditions for PCD pharma franchise across India.

Indications

  • Type-2 DM uncontrolled on dual OAD
  • Patients with significant hyperglycaemia
  • Combined cardiovascular and renal risk reduction

Mechanism of Action

Linagliptin inhibits DPP-4, prolonging incretin activity to enhance glucose-dependent insulin secretion. Dapagliflozin inhibits renal SGLT2, increasing urinary glucose excretion. Metformin activates AMPK to reduce hepatic glucose output and improve peripheral insulin sensitivity. The triple combination covers three complementary glycaemic mechanisms.

Dosage & Administration

['Adults: 1 tablet once daily in the morning', 'Swallow whole', 'Take with food to minimise GI side effects', 'Use under physician supervision']

Side Effects

['GI upset (metformin)', 'Genital mycotic infection', 'Urinary tract infection', 'Polyuria', 'Nasopharyngitis']

Contraindications & Precautions

['Type-1 diabetes', 'History of diabetic ketoacidosis', 'eGFR < 30', 'Severe hepatic impairment', 'Active urogenital infection', 'Pregnancy and breastfeeding']

Storage

Store below 25°C.

PCD Pharma Franchise & Third-Party Manufacturing
Linaglite-DM 5/10/500 Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →

Frequently Asked Questions

q

a

q

a

q

a

q

a

q

a

Related Products

B2B Disclaimer: This page is part of a Business-to-Business (B2B) pharmaceutical catalog intended for distributors, PCD franchise partners and healthcare professionals. Information provided is for commercial and educational reference only. Not for consumer sale. Patients must not self-medicate; please consult a qualified medical practitioner. All trade inquiries are subject to valid Drug License and GST documentation.